ANTIPODES PARTNERS Ltd
Position in REGN — Regeneron Pharmaceuticals, Inc.
CIK 1652442
ROYAL EXCHANGE, C3
Position in REGN
as of Mar 31, 2026
· filed May 5, 2026
Position Value
$74,946
+$75 QoQ
Shares Held
97
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in REGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026ANTIPODES PARTNERS Ltd holds $54,404,721 across 20 Biotechnology names. REGN ranks #5 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
145,310 | $48,078,719 | |
| 2 | HUMA |
Humacyte, Inc.
|
5,723,750 | $3,474,316 | |
| 3 | GPCR |
Structure Therapeutics Inc.
|
45,361 | $2,186,400 | |
| 4 | IMNM |
Immunome Inc.
|
7,818 | $170,979 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
This page
|
97 | $74,946 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
127 | $56,710 | |
| 7 | TARS |
Tarsus Pharmaceuticals, Inc.
|
555 | $38,933 | |
| 8 | ARGX |
Argenx SE
|
50 | $36,512 |
All Filings in REGN
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $74,946 | 97 | Shares | Sole | 2026-05-05 | |
| 2025-12-31 | $74,871 | 97 | Shares | Sole | 2026-02-05 | |
| No filing history on record for this holder in this stock. | ||||||